Location of Repository

Challenges for heart disease stem cell therapy

By Jane Hoover-Plow and Yanqing Gong

Abstract

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. The use of stem cells to improve recovery of the injured heart after myocardial infarction (MI) is an important emerging therapeutic strategy. However, recent reviews of clinical trials of stem cell therapy for MI and ischemic heart disease recovery report that less than half of the trials found only small improvements in cardiac function. In clinical trials, bone marrow, peripheral blood, or umbilical cord blood cells were used as the source of stem cells delivered by intracoronary infusion. Some trials administered only a stem cell mobilizing agent that recruits endogenous sources of stem cells. Important challenges to improve the effectiveness of stem cell therapy for CVD include: (1) improved identification, recruitment, and expansion of autologous stem cells; (2) identification of mobilizing and homing agents that increase recruitment; and (3) development of strategies to improve stem cell survival and engraftment of both endogenous and exogenous sources of stem cells. This review is an overview of stem cell therapy for CVD and discusses the challenges these three areas present for maximum optimization of the efficacy of stem cell therapy for heart disease, and new strategies in progress

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3295632
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2008). a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther.
    2. (2010). A longterm follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells.
    3. (2010). A novel technology for hematopoietic stem cell expansion using combination of nanofiber and growth factors. Recent Pat Nanotechnol.
    4. A pharmacokineticpharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther.
    5. (2000). A randomized Phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pr etreated patients with Hodgkin’s disease or non-Hodgkin’s l ymphoma. Bone Marrow Transplant.
    6. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
    7. A role for Wnt signalling in self-renewal of haematopoietic stem cells.
    8. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells.
    9. (2004). Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program.
    10. Adipose tissue-derived stem cells inhibit neointimal formation in a paracrine fashion in rat femoral artery.
    11. (2009). Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol.
    12. Adipose tissue: a new source for cardiovascular repair.
    13. (2008). Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium. Mol Ther.
    14. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes.
    15. Adult cardiac stem cells are multipotent and support myocardial regeneration.
    16. Adult stem cells for cardiac tissue engineering.
    17. Angiopoietinlike 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation.
    18. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
    19. Bone marrow cells regenerate infarcted myocardium.
    20. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI)
    21. (2004). Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor. Basic Res Cardiol.
    22. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction.
    23. (2010). Car diogenic induction of pluripotent stem cells streamlined through a conserved SDF-1/VEGF/BMP2 integrated network. PLoS One.
    24. Cardiac cell repair therapy: a clinical perspective. Mayo Clin
    25. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction.
    26. Cardiac progenitor cells in brown adipose tissue repaired damaged my ocardium.
    27. (2007). Cardiac stem cells in brown adipose tissue express CD133 and induce bone marrow nonhematopoietic cells to differentiate into cardiomyocytes. Stem Cells.
    28. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised Phase 1 trial.
    29. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.
    30. Cell therapy for cardiovascular disease: a comparison of methods of delivery.
    31. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI).
    32. (2004). Characterization of hematopoietic progenitor mobilization in protease-deficient mice.
    33. Chronic AMD3100 antagonism of SDF1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction.
    34. Clinical trials for stem cell therapies.
    35. (2012). ClinicalTrials.gov [homepage on the Internet]. Available from: http:// www.ClinicalTrials.gov. Accessed
    36. Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration.
    37. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc Revasc Med.
    38. (2011). Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells. Stem Cells.
    39. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells.
    40. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.
    41. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium.
    42. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins.
    43. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction.
    44. (2005). Cycling G1 CD34+/CD38+ cells potentiate the motility and engraftment of quiescent G0 CD34+/CD38-/low severe combined immunodeficiency repopulating cells. Stem Cells.
    45. cytokinedependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling.
    46. Cytokines and hematopoietic stem cell mobilization.
    47. De novo cardiomyocytes from within the activated adult heart after injury.
    48. Dedifferentiation and proliferation of mammalian cardiomyocytes.
    49. (2008). Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant.
    50. (2000). Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol.
    51. Differentiation and migration of Sca1+/CD31- cardiac side population cells in a murine myocardial ischemic model.
    52. (2011). Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Expert Opin Biol Ther.
    53. Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia.
    54. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide.
    55. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.
    56. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.
    57. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction.
    58. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction.
    59. Embryonic stem cell lines derived from human blastocysts.
    60. (2007). Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol.
    61. (2011). Endothelial progenitor cells: a novel tool for the therapy of ischemic diseases. Antioxid Redox Signal.
    62. Epicardium-derived cells: a new source of regenerative capacity.
    63. (2006). Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res.
    64. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury.
    65. Ex vivo expansion of cord blood.
    66. Ex vivo expansion of human hematopoietic stem and progenitor cells.
    67. (2008). Exploitation of stem cell homing for gene delivery. Expert Opin Biol Ther.
    68. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.
    69. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim.
    70. Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation.
    71. (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology.
    72. (2007). G-CSF-based stem cell therapy for the heartunresolved issues part A: paracrine actions, mobilization, and delivery. Congest Heart Fail.
    73. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice.
    74. Genetic manipulation of human embryonic stem cells in serum and feeder-free media. Methods Mol Biol.
    75. (2011). Growth factor-induced mobilization of cardiac progenitor cells reduces the risk of arrhythmias, in a rat model of chronic myocardial infarction. PLoS One.
    76. (2011). Guided orientation of cardiomyocytes on electrospun aligned nanofibers for cardiac tissue engineering.
    77. Heart regeneration: past, present and future.
    78. Heterogeneic nature of adult cardiac side population cells.
    79. Hierarchy of molecularpathway usage in bone marrow homing and its shift by cytokines.
    80. How do stem cells find their way home?
    81. Human cardiac stem cells.
    82. (2010). Human cardiospheres are a source of stem cells with cardiomyogenic potential. Stem Cells.
    83. (2007). Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol.
    84. Identification of endothelial cells and progenitor cell subsets in human peripheral blood. Curr Protoc Cytom. 2010;Chapter 9:Unit 9.33.1–11.
    85. (2007). Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res.
    86. In vivo detection of embryonic stem cell-derived cardiovascular progenitor cells using Cy3-labeled Gadofluorine M in murine myocardium.
    87. In vivo magnetic resonance imaging of injected endothelial progenitor cells after myocardial infarction in rats.
    88. (2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res.
    89. Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies.
    90. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction.
    91. (2011). Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation? Curr Hematol Malig Rep.
    92. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.
    93. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a Phase I/II clinical trial.
    94. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment.
    95. Mesenchymal stromal cells for cardiovascular disease.
    96. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells.
    97. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
    98. (2008). Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells.
    99. (2007). Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells.
    100. (2011). Neural crest-derived stem cells migrate and differentiate into cardiomyocytes after myocardial infarction. Arterioscler Thromb Vasc Biol.
    101. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination
    102. (2007). Noninvasive tracking of cardiac embryonic stem cells in vivo using magnetic resonance imaging techniques. Stem Cells.
    103. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product.
    104. Nuclear reprogramming strategy modulates differentiation potential of induced pluripotent stem cells.
    105. Optimizing mesenchymal stem cell-based therapeutics.
    106. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium.
    107. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation.
    108. Periostin is essential for cardiac healing after acute myocardial infarction.
    109. (2007). Periostin: more than just an adhesion molecule. Circ Res.
    110. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart.
    111. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother.
    112. Phases I–III clinical trials using adult stem cells. Stem Cells Int.
    113. (2011). Plasminogen regulates stromal cellderived factor-1/CXCR4-mediated hematopoietic stem cell mobilization by activation of matrix metalloproteinase-9. Arterioscler Thromb Vasc Biol.
    114. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages.
    115. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine.
    116. (2009). Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue. Stem Cell Rev.
    117. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture.
    118. Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: early cardiac retention of (m)Tc-labeled cells activity.
    119. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes.
    120. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma.
    121. Reassessment of Isl1 and Nkx2–5 cardiac fate maps using a Gata4-based reporter of Cre activity.
    122. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.
    123. (1998). Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med.
    124. Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure – a pilot study.
    125. (2012). Reporter gene PET for monitoring survival of transplanted endothelial progenitor cells in the rat heart after pretreatment with VEGF and atorvastatin.
    126. Resident cardiac progenitor cells: at the heart of regeneration.
    127. (2010). Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ Res.
    128. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction.
    129. Stem and progenitor cellbased therapy in ischaemic heart disease: promise, uncertainties, and challenges.
    130. Stem cell factor improves SCID-repopulating activity of human umbilical cord blood-derived hematopoietic stem/ progenitor cells in xenotransplanted NOD/SCID mouse model.
    131. Stem cell therapy for heart diseases. Br Med Bull.
    132. Stem cell therapy in acute myocardial infarction: a review of clinical trials.
    133. Stem cells and growth factor delivery systems for cardiovascular disease.
    134. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life.
    135. Stem cells and the niche: a dynamic duo.
    136. Stem cells in clinical practice: applications and warnings.
    137. (2010). Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol.
    138. SWIFT detection of SPIOlabeled stem cells grafted in the myocardium.
    139. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol.
    140. Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice.
    141. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther.
    142. (2011). Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther.
    143. (2007). The adult human heart as a source for stem cells: repair strategies with embryonic-like progenitor cells. Nat Clin Pract Cardiovasc Med.
    144. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.
    145. The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets.
    146. (2007). The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell.
    147. The role of circulating endothelial progenitor cells in tumor angiogenesis.
    148. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
    149. (1995). The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen.
    150. (2008). Towards the second generation of skeletal myoblasts? Cardiovasc Res.
    151. Tracking down the stem cells of the intestine: strategies to identify adult stem cells.
    152. (2010). Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res.
    153. Transplantation of marrow-derived cardiac stem cells carried in designer self-assembling peptide nanofibers improves cardiac function after myocardial infarction.
    154. (2003). Use of matrix metalloproteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligandinduced hematopoietic progenitor cell mobilization or engraftment. Stem Cells.
    155. (2009). Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3 K/Akt pathway. Exp Cell Res.
    156. (2003). Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo.
    157. Working hypothesis to redefine endothelial progenitor cells.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.